A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

(2013) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits

(2010) Celine Ullrich et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Neural mechanisms of ageing and cognitive decline

(2010) Nicholas A. Bishop et al.   NATURE

Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process

(2010) Bart De Strooper   PHYSIOLOGICAL REVIEWS

Inflammation, Cytokines, Immune Response, Apolipoprotein E, Cholesterol, and Oxidative Stress in Alzheimer Disease: Therapeutic Implications

(2010) Giuseppina Candore et al.   REJUVENATION RESEARCH

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

(2009) F. Patti et al.   Multiple Sclerosis Journal

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience